Clinical Trial Update: Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pazopanib (GW786034) in subjects with relapsed or refractory multiple myeloma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED